Physician profile
Christopher Kolibash
NPI 1043228414
$42,241.25
in general payments reported to CMS, 2019-2025
22 companies · $4,276 in 2025
The $4,276 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $6,823 · 2021: $2,376 · 2022: $3,295 · 2023: $7,805 · 2024: $6,383 · 2025: $4,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $10K · Food and Beverage: $8,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $10,338.77 |
| Food and Beverage | $8,125.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $18,394.79 | 2019-2025 | Aveir, Accent, Ensite Precision |
| Boston Scientific Corporation | $9,219.23 | 2019-2025 | Watchman Access System, Watchman Flx, Farapulse |
| Medtronic, INC. | $5,045.00 | 2021-2025 | Pulseselect, Arctic Front Advance, Affera Mapping System |
| Atricure, INC. | $2,996.66 | 2019-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Medtronic Vascular, INC. | $2,925.26 | 2019-2020 | |
| Biotronik INC. | $1,467.20 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $776.92 | 2019-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $417.79 | 2019-2024 | Optimizer |
| Janssen Pharmaceuticals, INC | $199.04 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $150.67 | 2019-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.13 | 2023-2025 | Jardiance |
| Recor Medical INC | $142.70 | 2024 | Paradise Renal Denervation System |
| Pfizer INC. | $127.64 | 2019-2025 | |
| Abiomed | $48.95 | 2021-2024 | Impella |
| Cardiva Medical, INC. | $40.85 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $26.75 | 2024 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $26.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.54 | 2023 | |
| Watermark Medical, INC. | $17.67 | 2025 | |
| Irhythm Technologies, INC. | $17.05 | 2023 | Zio Xt Patch |
| Kiniksa Pharmaceuticals, LTD. | $16.48 | 2023 | Arcalyst |
| Biosense Webster, INC. | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kolibash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.